Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo, Apremilast
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
24
States / cities
Mountain Brook, Alabama • Sacramento, California • Whittier, California + 21 more
Terminated Phase 2Phase 3 Interventional Results available

Psoriatic Arthritis Study of Izokibep

NCT05623345
Conditions
Psoriatic Arthritis
Interventions
Izokibep, Placebo to izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more
Conditions
Arthritis, Psoriatic Arthritis
Interventions
Mobile Application
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Psoriatic Arthritis
Interventions
Guselkumab, Golimumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Loxahatchee Groves, Florida • Plant City, Florida • Riverview, Florida + 11 more
Completed No phase listed Observational Accepts healthy volunteers

DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA

NCT03011242
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, New York
Conditions
Arthritis, Psoriatic
Interventions
CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
27
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more
Conditions
Psoriatic Arthritis
Interventions
Dose A VTX958, Dose B VTX958, Placebo
Drug
Lead sponsor
Ventyx Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • Clearwater, Florida + 12 more
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, New York
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Conditions
Psoriatic Arthritis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
21
States / cities
Peoria, Arizona • Aventura, Florida • Palm Harbor, Florida + 17 more
Conditions
Psoriatic Arthritis
Interventions
Methotrexate, Anti-TNF
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • San Diego, California • Palm Harbor, Florida + 28 more
Conditions
Arthritis, Psoriatic
Interventions
Apremilast (CC-10004), Apremilast (CC-10004) Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Mesa, Arizona • Covina, California • Encino, California + 48 more
Conditions
Psoriatic Arthritis
Interventions
Placebo, Bimekizumab
Other · Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
San Diego, California • Aventura, Florida • Hagerstown, Maryland + 10 more
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Psoriatic Arthritis, Obesity
Interventions
Ixekizumab, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
81
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Boise, Idaho • Lexington, Kentucky • Baton Rouge, Louisiana + 17 more
Conditions
Psoriatic Arthritis
Interventions
Open label H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lansing, Michigan
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
Network
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
La Jolla, California • Seattle, Washington
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
Active, not recruiting Phase 2 Interventional

A Study of SPY072 in Rheumatic Disease

NCT07148414
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease
Interventions
SPY002-072, Placebo
Drug
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Avondale, Arizona • Tucson, Arizona • Chula Vista, California + 14 more
Conditions
Psoriatic Arthritis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
59
States / cities
Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Phoenix, Arizona • San Diego, California • Tustin, California + 30 more